1,582 results on '"Ratain, Mark J."'
Search Results
2. Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)
3. Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders
4. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies
5. Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
6. Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
7. Genomewide Meta‐Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent‐Induced Sensory Peripheral Neuropathy
8. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
9. Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
10. A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance)
11. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
12. Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan
13. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
14. Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings
15. Lurbinectedin-induced thrombocytopenia: the role of body surface area
16. Implementation of pharmacogenomics into inpatient general medicine
17. Combination therapy patents: a new front in evergreening
18. Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application
19. A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
20. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial
21. Oncology Drug Prescribing: The Influences of Greed and Fear
22. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine
23. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
24. Optimizing the doses of cancer drugs after usual dose finding.
25. Negative innovation: when patents are bad for patients
26. Optimizing the doses of cancer drugs after usual dose finding
27. Special designations and the US Food and Drug Administration’s “dual mandate”
28. Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance)
29. Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
30. Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide
31. Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics
32. Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care
33. Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation
34. UGT1A and UGT2B Genetic Variation Alters Nicotine and Nitrosamine Glucuronidation in European and African American Smokers
35. Patient-provider communications about pharmacogenomic results increase patient recall of medication changes
36. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy
37. Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance)
38. Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies
39. Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions
40. Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study
41. Alternative dosing regimens for atezolizumab: right dose, wrong frequency
42. Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients
43. Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
44. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia
45. Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist
46. Pharmacogenomics and Patient Care: One Size Does Not Fit All
47. A Genome-Wide Association Study Identifies Novel Loci for Paclitaxel-Induced Sensory Peripheral Neuropathy in CALGB 40101
48. Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
49. Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system
50. US Government Payer–Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.